Bora Pharmaceutical Holdings, LLC, a Key Subsidiary of Powarui, Announces Acquisition of U.S. Drug Approval and Related Rights
AI Summary (NQ-processed)
Bora Pharmaceutical Holdings, LLC, a significant subsidiary of Powarui, has acquired the U.S. regulatory approval and associated rights for Vigadrone. The transaction amounts to USD 45 million, funded by internal capital.
AI Analysis
Frequently Asked Questions
Q: What was the purpose of Powarui's transaction?
A: To expand product value and establish a strategic presence in the U.S. market.
Q: What was the transaction amount?
A: USD 45 million, funded by internal capital.
Q: Was the audit committee involved?
A: Yes, approved on June 18, 2026.
Q: What is Vigadrone used for?
A: It is a neurological drug primarily used for epilepsy treatment.
Q: What comes next after this acquisition?
A: U.S. commercialization plans and distribution partnerships are expected.